[Hemorrhagic congenital diseases: What can be the future of plasma-derived products against recombinants?].
Until 1990, congenital hemorrhagic disorders were treated by plasma-derived concentrates. The first recombinant drug, recombinant factor VIII was available after this date and few years later recombinant factor IX could also be proposed to patients. The evolution of market share in France was different between these two drugs: while recombinant factor VIII took a large place in hemophilia A treatment (85%), plasma-derived factor IX represent 50% of the French market. In the next years, the arrival of long-acting antihemophilic factors may lead to the dramatically reduce the amount of plasma-derived antihemophilic factors used to treat hemophilia. For rare bleeding coagulation disorders, plasma-derived concentrates are still widely used, while they are the only concentrates available in most diseases. This situation is unlikely to evolve significantly in the next years.
Département d'hématologie biologique, hôpital Saint-Éloi, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France. Electronic address: schvedjf@aol.com.
J-F
JF
Schved
D000818:Animals; D030801:Animals, Genetically Modified; D001779:Blood Coagulation Factors / Q000235:genetics / Q000302:isolation & purification / Q000600:supply & distribution / Q000627:therapeutic use*; D004363:Drug Utilization; D005260:Female; D005544:Forecasting; D005602:France / Q000453:epidemiology; D006474:Hemorrhagic Disorders / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D010949:Plasma; D015995:Prevalence; D011817:Rabbits; D011994:Recombinant Proteins / Q000600:supply & distribution / Q000627:therapeutic use*
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins
Antihemophilic factors; Déficits rares de la coagulation; Dérivés plasmatiques; Facteurs antihémophiliques; Hemophilia; Hémophilie; Plasma-derived concentrates; Produits recombinants; Rare bleeding disorders; Recombinant